acf/google-ad-placement

<ul>
	<li>The&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/08/g22553381/fda-clears-brainsway-deep-tms-system-for-decreasing-anxiety-symptoms-in-depressed-patients" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">FDA has cleared</a>&nbsp;BrainsWay Ltd&#39;s&nbsp;BWAY Deep Transcranial Magnetic Stimulation (Deep TMS) System to reduce comorbid anxiety symptoms in adult patients with depression, also known as anxious depression.</li>
	<li>BrainsWay submitted data from 573 patients in support of its application to the FDA.&nbsp;</li>
	<li>The data demonstrated a treatment effect that was consistent, robust, and clinically meaningful for decreasing anxiety symptoms in adult patients suffering from a major depressive disorder.&nbsp;</li>
	<li>An analysis of the BrainsWay data found favorable outcomes with Deep TMS compared to sham or medication as a standard of care.&nbsp;</li>
	<li>Related content: Benzinga&#39;s Full&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/calendars/fda#historical" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">FDA Calendar</a>.</li>
	<li>Price Action:&nbsp;BWAY Stock is up 18.4% at $9.00 during the premarket session on the last check Wednesday.</li>
</ul>

Long Ideas

News

Comments